[1] [2] Patients with a history of diabetic retinopathy require careful consideration, as the SUSTAIN-6 trial identified a higher incidence of retinopathy complications in the semaglutide group, particularly in those with pre-existing retinopathy and rapid improvement in blood glucose control
Instead, your GLP-1 dosage is carefully adjusted based on your bodys response, including appetite changes, digestive tolerance, energy levels, and overall progress
Compounded semaglutide is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality
They occur in the labial, buccal mucosa and floor of the mouth
In the study by Kong et al
With that said, Seigerman expects GLP-1s in particular to continue to face pricing pressure